IGC Pharma Sees 80% Enrollment in Phase 2 CALMA Alzheimer’s Agitation Trial
IGC Pharma’s Phase 2 CALMA trial for agitation in Alzheimer’s dementia has reached approximately 80% patient enrollment and is moving toward final enrollment. The company launched a caregiver-focused podcast discussion to raise awareness of agitation symptoms and enhance patient engagement in the ongoing clinical study.
1. Phase 2 CALMA Enrollment Progress
IGC Pharma’s CALMA trial has enrolled around 80% of planned patients for its Phase 2 study targeting agitation in Alzheimer’s dementia, positioning the study to enter its final enrollment phase in the coming weeks.
2. Caregiver-Focused Podcast Outreach
The company participated in a caregiver-directed podcast episode featuring clinical leaders to discuss the clinical significance of agitation, aiming to educate caregivers on symptom recognition and underscore the trial’s requirements for patient engagement.
3. Strategic Importance of Awareness Efforts
By enhancing caregiver awareness of agitation through this outreach, IGC Pharma expects to support smoother trial operations, potentially accelerating enrollment completion and reinforcing its commitment to translating clinical research into patient-centered care.